MCM
SKYE icon

MAI Capital Management’s Skye Bioscience SKYE Stock Holding History

MAI Capital Management’s Portfolio SKYE Stock Details SKYE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-32
Closed -$126 – 4496
2025
Q3 		$126 Hold
32
– – ﹤0.01% 3731
2025
Q2 		$134 Hold
32
– – ﹤0.01% 3885
2025
Q1 		$51 Hold
32
– – ﹤0.01% 3389
2024
Q4 		$91 Buy
+32
New +$134 ﹤0.01% 3433

Other funds holding SKYE

5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

MAI Capital Management's SKYE Position: Q4 2025 in Review

MAI Capital Management sold out of Skye Bioscience (SKYE) in Q4 2025, closing a stake of 32 shares — an estimated $126 sold.

MAI Capital Management first reported a position in SKYE in Q4 2024 and held it in 4 quarters. The position peaked at $134 in Q2 2025. 50 funds tracked by Wall St. Rank hold SKYE as of Q4 2025.

  • MAI Capital Management reported no remaining Skye Bioscience position as of Q4 2025 after selling out during the quarter.
  • MAI Capital Management sold 32 Skye Bioscience shares in Q4 2025, an estimated $126.
  • MAI Capital Management first reported a position in Skye Bioscience in Q4 2024 and held it in 4 quarters.
  • MAI Capital Management's Skye Bioscience position peaked at $134 in Q2 2025.
  • 50 funds tracked by Wall St. Rank held Skye Bioscience as of Q4 2025.

Based on MAI Capital Management's 13F filing for Q4 2025, filed 13 Feb 2026.